Sign in

NCT03799354Recruiting

Study on Impact of Maximal Strength Training in Patients With COPD

Study on Impact of Maximal Strength Training in Patients With COPD: Physiological and Clinical Implications

Source: ClinicalTrials.gov · Last updated 4 Nov 2026

Brief summary (registry, in English)

In the context of pulmonary rehabilitation of COPD patients, recent guidelines and metanalysis describe that Resistance Training (RT) can be successfully performed alone or in conjunction with Endurance Training (ET) without evidence of adverse events. Maximal Strength Training (MST) is a kind of RT typically performed at \~85-90% of 1RM with maximal velocity to be developed in the concentric phase. Recent literature indicates a significant amelioration on the Rate of Force Development (RFD) after MST in healthy subjects, post-menopausal woman and older populations. When comparing to the conventional ET, MST generates a little change in muscle mass (no hypertrophy), but a much greater improvement in the RFD. It has been described that neural adjustments play a major role in the MST-induced adaptations. MST is also well documented to improve aerobic endurance by improving walking work efficiency. Only a small cohort study of COPD patients was conducted, describing that MST can meaningfully improve strength and RFD, with an increase of around 32% for mechanical efficiency and a decrease of the perceived effort during submaximal job. This improvement could determine best performances in daily activities and a best quality of life. The main aims of this physiological pilot randomized controlled trail will be to evaluate feasibility and efficacy of the MST compared to standard ET on strength, effort tolerance, fatigue, economy of walking, dyspnea and risk of falls in a populations of COPD patients, in a short and middle term (6 months).

Status (registry)
Recruiting
Study type
Interventional
Enrollment
20 (estimated)
First submitted
4 Dec 2018
Start date
18 Sept 2019
Primary completion date
28 Feb 2027
Lead sponsor
Istituti Clinici Scientifici Maugeri SpA
Diseases
COPD
NCT number
NCT03799354

What you commit to

  • Study type: Interventional
  • Planned participants: 20
  • From 18 Sept 2019 to the primary completion date, 28 Feb 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • long oxygen therapy use.

Other illness

  • pulmonary diseases other than COPD
  • type II diabetes or other metabolic diseases
  • malign disease
  • a respiratory tract infection within the last 4 wks

Who the study is looking for

  • COPD clinical definition according to GOLD guidelines with forced expiratory volume (FEV1)/ forced vital capacity (FVC) \< 70%, and FEV1 \< 50% of predicted
  • stable clinical condition

Age in the registry: 50 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
ICS Maugeri IRCCS, Respiratory Rehabilitation of the Institute of Lumezzane
Coordinator of this site? Confirm its status
LumezzaneItalyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.